Novel therapeutic compound tuftsin- XXXX attenuate @entity1753 .

@entity1 @entity15310 @entity625 @entity637 @entity776 @entity19 @entity635 @entity10062 @entity1753 @entity1618 @entity1961 @entity23540 @entity6689 @entity3744 @entity636 @entity2945 @entity792 @entity309
UNASSIGNED: Treatment with helminthes and helminthes ova, improved clinical symptoms of several @entity792 in @entity1 and in animal models. @entity2945 (PC) was proven to be the immunomodulatory molecule. We aimed to decipher the tolerogenic potential of @entity15310 ( @entity15310 ), a novel helminth based compound in @entity1753 ( @entity1753 ) in a @entity19 model of @entity309 ( @entity309 ). @entity1753 DBA @entity19 were treated with @entity15310 , subcutaneously (5  g/0.1ml) or orally (250  g/0.1ml), starting prior to disease induction. The control groups were treated with PBS. Collagen antibodies were tested by ELISA, cytokines protein levels by ELISA kits and T-regulatory (Treg) and B-regulatory (Breg) cells phenotypes by @entity10062 . @entity15310 treated @entity19 had a significant lower @entity625 score 1.5 in comparison with control @entity19 11.8 (p<0.0001) both in subcutaneous and orally treated groups at Day 31. Moreover, histology analysis demonstrated highly inflamed joints in control @entity19 , whereas @entity15310 treated @entity19 maintained normal joint structure. Furthermore, @entity15310 decreased the titers of circulating collagen II antibodies in @entity19 sera (p<0.0001), enhanced expression of @entity1618 (p<0.0001), and inhibited production of @entity637 , @entity636 and @entity635 (p<0.0001). @entity15310 significantly expanded the @entity1961 (   +) CD25(+)    @entity3744 (+   ) Treg cells and @entity6689 (high) @entity776 (high) @entity23540 (+) Breg cells phenotypes (p<0.0001) in treated @entity19 . Our data indicate that treatment with @entity15310 attenuates @entity1753 in @entity19 demonstrated by low arthritic score, and normal joints histology. @entity15310 treatment reduced pro-inflammatory cytokines and increased anti-inflammatory cytokine expression, as well as expansion of Treg and Breg cells. Our results may lead to a new approach for a natural therapy for early @entity309 onset. This article is protected by copyright. All rights reserved.
